AU2023269033A1 - Menin-mll inhibitors for the treatment of cancer - Google Patents
Menin-mll inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- AU2023269033A1 AU2023269033A1 AU2023269033A AU2023269033A AU2023269033A1 AU 2023269033 A1 AU2023269033 A1 AU 2023269033A1 AU 2023269033 A AU2023269033 A AU 2023269033A AU 2023269033 A AU2023269033 A AU 2023269033A AU 2023269033 A1 AU2023269033 A1 AU 2023269033A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- inhibitor
- administered
- menin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339635P | 2022-05-09 | 2022-05-09 | |
| US63/339,635 | 2022-05-09 | ||
| PCT/US2023/021604 WO2023220098A1 (en) | 2022-05-09 | 2023-05-09 | Menin-mll inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023269033A1 true AU2023269033A1 (en) | 2024-11-21 |
Family
ID=88730925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023269033A Pending AU2023269033A1 (en) | 2022-05-09 | 2023-05-09 | Menin-mll inhibitors for the treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250295661A1 (enExample) |
| EP (1) | EP4522174A4 (enExample) |
| JP (1) | JP2025516558A (enExample) |
| KR (1) | KR20250020447A (enExample) |
| CN (3) | CN120514709A (enExample) |
| AU (1) | AU2023269033A1 (enExample) |
| CA (1) | CA3252288A1 (enExample) |
| IL (1) | IL316829A (enExample) |
| MX (1) | MX2024013787A (enExample) |
| WO (1) | WO2023220098A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| AR125866A1 (es) * | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
| KR20260099138A (ko) * | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| WO2025188611A1 (en) * | 2024-03-04 | 2025-09-12 | Dana-Farber Cancer Institute, Inc. | Chemical matters for targeting leukemic complex proteins |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752639B2 (en) * | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| ES2831084T3 (es) * | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| CN110691779B (zh) * | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| AU2019337547A1 (en) * | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| JP2022503792A (ja) * | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| WO2020142557A1 (en) * | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Irreversible inhibitors of menin-mll interaction |
| IL297039A (en) * | 2020-04-07 | 2022-12-01 | Syndax Pharmaceuticals Inc | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
| JP7891524B2 (ja) * | 2021-08-11 | 2026-07-16 | バイオメア フュージョン，インコーポレイテッド | 真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤 |
-
2023
- 2023-05-09 CN CN202510715666.3A patent/CN120514709A/zh active Pending
- 2023-05-09 CN CN202510715560.3A patent/CN120531737A/zh active Pending
- 2023-05-09 IL IL316829A patent/IL316829A/en unknown
- 2023-05-09 WO PCT/US2023/021604 patent/WO2023220098A1/en not_active Ceased
- 2023-05-09 CA CA3252288A patent/CA3252288A1/en active Pending
- 2023-05-09 JP JP2024566255A patent/JP2025516558A/ja active Pending
- 2023-05-09 US US18/863,966 patent/US20250295661A1/en active Pending
- 2023-05-09 KR KR1020247040587A patent/KR20250020447A/ko active Pending
- 2023-05-09 AU AU2023269033A patent/AU2023269033A1/en active Pending
- 2023-05-09 EP EP23804162.8A patent/EP4522174A4/en active Pending
- 2023-05-09 CN CN202380049030.9A patent/CN119403557A/zh active Pending
-
2024
- 2024-11-07 MX MX2024013787A patent/MX2024013787A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4522174A1 (en) | 2025-03-19 |
| MX2024013787A (es) | 2025-02-10 |
| CN119403557A (zh) | 2025-02-07 |
| CA3252288A1 (en) | 2023-11-16 |
| JP2025516558A (ja) | 2025-05-30 |
| EP4522174A4 (en) | 2026-05-20 |
| CN120514709A (zh) | 2025-08-22 |
| US20250295661A1 (en) | 2025-09-25 |
| WO2023220098A1 (en) | 2023-11-16 |
| IL316829A (en) | 2025-01-01 |
| KR20250020447A (ko) | 2025-02-11 |
| CN120531737A (zh) | 2025-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250295661A1 (en) | Menin-mll inhibitors for the treatment of cancer | |
| Song et al. | Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study | |
| EP4149455B1 (en) | Combination of the atr inhibitor azd6738 and paclitaxel for use in treating melanoma in patients who previously received immunotherapy | |
| US12048698B2 (en) | Treatment of HER2 positive cancers | |
| JP2022082565A (ja) | がんを処置するための方法 | |
| UA126970C2 (uk) | Комбінації кабозантинібу і атезолізумабу для лікування раку | |
| WO2020191326A1 (en) | Treatment of acute myeloid leukemia (aml) with venetoclax failure | |
| UA118846C2 (uk) | Комбінована терапія | |
| US20240139196A1 (en) | Combination treatments in difficult to treat patients with advanced and/or metastatic trop-2 overexpressing cancers | |
| US20240131030A1 (en) | Methods of treating b-cell proliferative disorder | |
| UA126313C2 (uk) | Комбінована терапія | |
| Zeng et al. | Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study | |
| US20240307397A1 (en) | Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma | |
| WO2025014784A1 (en) | Treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent | |
| Kalakonda et al. | Selinexor in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (SADAL): A Single-Arm Multinational Phase 2 Trial | |
| KR20260005936A (ko) | 간에만 전이된 포도막 흑색종의 치료 방법 | |
| WO2025199440A1 (en) | Methods of treating liposarcoma using a pyrazole compound | |
| EA044960B1 (ru) | Лечение her2-положительных злокачественных новообразований | |
| AU2017261826A1 (en) | Methods and compositions for treating advanced stage non-small cell lung cancer |